Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,845 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,845 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $23.38, for a total transaction of $66,516.10. Following the completion of the sale, the chief financial officer owned 44,927 shares of the company’s stock, valued at approximately $1,050,393.26. This represents a 5.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, May 5th, Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.60, for a total value of $233,313.00.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX traded down $0.02 on Thursday, reaching $23.58. The company’s stock had a trading volume of 1,248,824 shares, compared to its average volume of 1,517,187. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $25.08. The business’s 50-day moving average price is $20.31 and its two-hundred day moving average price is $17.78. The firm has a market cap of $2.45 billion, a PE ratio of -6.83 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The business had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. As a group, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.82 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NRIX. Larson Financial Group LLC grew its position in Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after purchasing an additional 1,190 shares in the last quarter. California State Teachers Retirement System increased its stake in Nurix Therapeutics by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock valued at $1,290,000 after buying an additional 1,476 shares during the last quarter. Intesa Sanpaolo Wealth Management bought a new stake in Nurix Therapeutics during the 4th quarter worth about $31,000. Royal Bank of Canada lifted its position in Nurix Therapeutics by 17.6% during the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock worth $206,000 after buying an additional 1,623 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of Nurix Therapeutics by 8.2% during the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after buying an additional 1,674 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Jefferies Financial Group boosted their price objective on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Robert W. Baird upped their target price on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. UBS Group increased their target price on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Finally, BTIG Research restated a “buy” rating and issued a $32.00 price target on shares of Nurix Therapeutics in a report on Friday, July 10th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.